Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

von Willebrand disease.

T S Zimmerman, Z M Ruggeri

    Human Pathology
    |February 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    von Willebrand disease (vWD) involves defects in von Willebrand factor (vWF), impacting platelet function and potentially factor VIII levels. This review covers vWD

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interaction of von Willebrand factor with platelets and the vessel wall.

    Hamostaseologie·2015
    Same author

    Genetic deletion of platelet glycoprotein Ib alpha but not its extracellular domain protects from atherosclerosis.

    Thrombosis and haemostasis·2014
    Same author

    Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.

    Journal of thrombosis and haemostasis : JTH·2013
    Same author

    Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.

    Journal of thrombosis and haemostasis : JTH·2010
    Same author

    Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis.

    Journal of thrombosis and haemostasis : JTH·2006
    Same author

    Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

    Journal of thrombosis and haemostasis : JTH·2006
    Same journal

    TRPS1 and GATA3 Expression in BRG1/SMARCA4-deficient Malignant Neoplasms.

    Human pathology·2026
    Same journal

    Clinicopathologic and Molecular Characteristics of Acral Melanomas Harboring RARA Fusions.

    Human pathology·2026
    Same journal

    Clinical Impact of Second Opinion Consultation in Bladder Biopsies and Transurethral Resection of Bladder Tumors.

    Human pathology·2026
    Same journal

    Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.

    Human pathology·2026
    Same journal

    Mixed Phenotype Acute Leukemia: Lineage Assignment, Immunophenotypic Classification and Genetic Insights.

    Human pathology·2026
    Same journal

    Chronic myelomonocytic leukemia revisited: A comprehensive review with emphasis on the oligomonocytic subtype.

    Human pathology·2026
    See all related articles

    Area of Science:

    • Hematology
    • Molecular Biology
    • Genetics

    Background:

    • von Willebrand disease (vWD) is a complex bleeding disorder.
    • It stems from quantitative or qualitative defects in von Willebrand factor (vWF).
    • Secondary factor VIII deficiency can also occur, causing coagulation defects.

    Purpose of the Study:

    • To review the current understanding of von Willebrand factor (vWF) and factor VIII.
    • To explore their structures and functions in relation to vWD.
    • To discuss the pathogenesis, diagnosis, classification, and therapy of vWD.

    Main Methods:

    • Literature review of scientific articles and clinical studies.
    • Analysis of existing data on vWF and factor VIII structure-function relationships.

    Related Experiment Videos

  • Synthesis of information regarding vWD pathogenesis, diagnosis, classification, and treatment.

    • Main Results:

    • vWF defects directly impair platelet function, leading to prolonged bleeding times.
    • The complex of vWF and factor VIII in plasma is crucial for hemostasis.
    • Understanding these molecular interactions is key to managing vWD.

    Conclusions:

    • Current knowledge of vWF and factor VIII structures and functions is essential for vWD management.
    • Accurate diagnosis, classification, and targeted therapy rely on this understanding.
    • Further research into the vWF-factor VIII complex may reveal new therapeutic strategies.